Eniola's most defensible angle — if applying — would be to reframe TOPOLOGIX as an early-stage immunology drug-protein interaction startup: TDA-based persistent homology applied to immunological drug targets (e.g. checkpoint inhibitors, CAR-T antigen mapping, antibody–epitope binding topology) could credibly slot under the 'Novel Development of New Immunological Therapies' and 'Enhancing Immunology Drug Development and Safety' sub-themes. She would need to position herself as the founding CEO of TOPOLOGIX (not as an independent researcher), articulate a pharma-ready prototype that immunology drug developers could license today, and recruit a co-founder or technical co-lead to satisfy the 2-representative minimum. The CCT model's Bayesian clinical trial architecture (preprint 3) could be framed as supporting immunotherapy adherence or irAE prediction as a secondary angle, though the stretch is visible to reviewers.